

WAREHOUSE LOCAL 730 HEALTH AND WELFARE FUND

January 2021 – December 2021

Savings Results

Pharmacy Updates

Member Engagement

June 6, 2022

Graham Hayes, Sr. Client Manager

Gloria Richardson-Davis, Client Engagement Manager

Jada Wuthrich, Pharmacy Account Executive

Greta Kreidler, VP Existing Business, Sales Manager

Together, all the way.®



PPO and Out of Network Savings Program January 2021 – December 2021

In Network	Charges	Network Allowed	Network Savings	%
Inpatient	\$773,771.17	\$601,268.15	\$172,503.02	22.3%
Outpatient	\$1,417,037.81	\$808,058.65	\$608,979.16	43.0%
Physician	\$2,603,727.31	\$1,192,480.31	\$1,411,247.00	54.2%
Total	\$4,794,536.29	\$2,601,807.11	\$2,192,729.18	45.7%

Out of Network Savings Program	Charges	Network Allowed	Network Savings	%
Outpatient	\$60,031.93	\$13,173.92	\$46,858.01	78.1%
Physician	\$223,316.63	\$101,826.84	\$121,489.79	54.4%
Total	\$283,348.56	\$115,000.76	\$168,347.80	59.4%



Total Year To Date Savings January 2021 – December 2021

	Savings
PPO Network Savings	\$2,192,729
Out of Network Savings	\$168,348
Utilization Management Savings	\$41,246
Case Management Savings	\$20,883
Outpatient Care Management Savings	\$51,848
Total Year To Date Savings	\$2,475,054

PPO and Out of Network Savings Program January 2022 – March 2022

In Network	Charges	Network Allowed	Network Savings	%
Inpatient	\$18,402.01	\$17,987.99	\$414.02	2.2%
Outpatient	\$337,026.56	\$179,145.57	\$157,880.99	46.8%
Physician	\$535,929.54	\$223,679.07	\$312,250.47	58.3%
Total	\$891,358.11	\$420,812.63	\$470,545.48	52.8%

Out of Network Savings Program	Charges	Network Allowed	Network Savings	%
Total	\$87,525.45	\$47,989.82	\$39,535.63	45.2%

Total Year To Date Savings January 2022 – March 2022

	Savings
PPO Network Savings	\$470,545
Out of Network Savings	\$39,536
Utilization Management Savings	\$22,236
Case Management Savings	\$1,190
Outpatient Care Management Savings	\$11,066
Total Year To Date Savings	\$544,573


PHARMACY




PHARMACY - TOTAL HEALTH INSIGHT OVERVIEW

PHARMACY KEY METRICS

	Base	Current	Trend	Norm
Total Rx Spend	\$881.1k	\$776.8k	-11.8%	
Rx Cost Share	9.0%	9.6%	0.6%	9.4%
Avg. \$ per Script	\$153	\$135	-11.8%	\$170
Generic Dispensing	92.4%	92.9%	0.6%	92.0%
Generic Substitution	98.7%	98.4%	-0.3%	97.7%
SRx as % of Total	52.8%	49.8%	-3.1%	50.5%



AVERAGE COST PER SCRIPT



TOP DRUGS BY SPEND

Base	Current	Drug Name	Condition
2	1	Biktarvy (SRx)	HIV
4	2	Humira Pen (SRx)	Arthritis
3	3	Humira(Cf) Pen (SRx)	Arthritis
6	4	Trulicity	Diabetes
-	5	Harvoni (SRx)	Hepatitis
7	6	Odefsey (SRx)	HIV
-	7	Dupixent Syringe (SRx)	Asthma
-	8	Actemra (SRx)	Arthritis
1	9	Gilenya (SRx)	Multiple Sclerosis
5	10	Atripla (SRx)	HIV

TOP 10 DRUG CLASSES


2021

Anti-Inflam Disease Modifiers
Antivirals, HIV Specific
Hypoglycemics
Asthma Related
Insulins
Hepatitis A/B/C
Multiple/Lateral Sclerosis
Vaccines
ACE/ARB
Lipid Lowering


2020

Antivirals, HIV Specific
Anti-Inflam Disease Modifiers
Multiple/Lateral Sclerosis
Hypoglycemics
Insulins
Asthma Related
ACE/ARB
Antiulcer
Narcotic Analgesics
Lipid Lowering

ACHIEVED SAVINGS



TOTAL SPECIALTY PLAN SPEND



Generic prescriptions represents 93% of drug volume and 34% of ingredient cost

July 2022 Clinical Formulary Update

Expanded choice and tighter controls through comprehensive drug review and actions

Changes under:



Medical (SpecialtyRx) benefit

- ✓ promote immune response, used for cancer treatment and for hypertension as examples. Changes promote preferred agents, generic alternatives and site of care management.



Pharmacy benefit

- ✓ **Specialty Drugs Under the Pharmacy Benefit** – include those used to treat HIV, cancer and Multiple Sclerosis (MS) as examples. Changes to important HIV drugs promote lower cost biosimilars which leads to better adherence - a key factor in maintaining good health. Oncology changes promote generics and preferred brands and MS drug therapy will first require Tecfidera to reduce the number and severity of relapses before other branded medications are considered for coverage.
- ✓ **Drugs Under the Pharmacy Benefit** – include a specific ADHD agent to ensure utilization is age appropriate. For Asthma/COPD, we'll drive toward preferred products and diabetes drug changes offer a stronger push toward metformin and discourage diabetic drug use off label for weight loss.
- ✓ **Also Targeting** – egregiously priced drugs (high cost compared to alternatives providing same health outcomes). Some drugs on Preventive Drug List are being removed to comply with Mental Health Parity rule. Customers who have been paying \$0 for CGM transmitters will now have to pay their regular copay/coinsurance in accordance with their plan. And finally there are a number of positive changes that effects new starts.



HEALTH CARE PROVIDERS

- Patient-specific letters to affected HCP with news/drug alternatives
- Posting on portal, newsletter article

PHARMACIES

- Blast fax with news and drug alternatives
- Posting on portal

External Customer Communications Letters/Emails Mail Dates:
April 1: Initial Notice
Mid-May: Second Notice
Mid-July: Final Notice

RECOMMENDED PROGRAM

- Patient Assurance Program
- Cigna 90 Now Exclusive



PATIENT ASSURANCE PROGRAM

Moving one step closer to helping every customer focus on what matters most: their wellbeing

1 IN 4 people
with diabetes have
cut back their dosage
**DUE TO
COST.¹**

Lower **COSTS**

Eligible customers pay no more than \$25 per 30-day supply of preferred and participating diabetes medications.² A 40% reduction from average out-of-pocket cost of \$41.50 in 2018.³

Better **Predictability**

Improve predictability and affordability for customers each time they fill an eligible Rx to drive adherence.

Smarter **Healthcare**

Change the medication affordability story and make a meaningful difference for your employees.

Collaboration with **drug makers** to provide a discount that goes directly to the customer at the point of sale.

There's **no fee** to enroll.

Included diabetes drug categories:⁴

- Preferred insulins
- Preferred non-insulin diabetes medications (DPP-4 inhibitors, GLP-1 agonists and SGLT2 inhibitors)


1. Journal of the American Medical Association: Internal Medicine, January 2019, Vol. 179 2. Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. If a plan provides coverage for certain prescription drugs with no cost-share, the customer may be required to use an in-network pharmacy to fill the prescription. Out-of-network coverage may be excluded or limited by plan terms. Clients must agree to provide "first dollar coverage" (prior to satisfaction of any applicable plan deductible). 3. Express Scripts internal analysis of claims, 2019. Participating drugs as of July 2020, subject to change. 4. Drugs eligible for the PAP discount vary based on Cigna Prescription Drug List.




Patient Assurance Program - Opportunity

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

The Patient Assurance Program improves customer affordability by capping customer cost share at \$25 per one-month supply for eligible medications. This discount is provided through arrangements with manufacturers to apply up to \$50 per one-month supply that goes directly to customer at point of sale.



Program value of \$2,498 available at point of sale for eligible drugs



23 customers would have cost share reduced to \$25 / script, saving \$2,498.

Top Customer Savings by Drug

Drug Name	Customers	Scripts	Current Cost Share	Projected Program Value
Trulicity	5	36	\$1,431	\$531
Farxiga	3	20	\$800	\$300
Jardiance	4	18	\$720	\$270
Other	19	86	\$3,547	\$1,397
Total	23	160	\$6,498	\$2,498

Comments

- Data includes only eligible drugs with cost share greater than \$25 per month
- \$2,498 of the program value is from manufacturer discounts at the point of sale

Maintenance medication program

Choose the program that works best for you

Voluntary

Choice: Customers can fill a 30-day or 90-day supply as prescribed by their physician

- **For 90-day fills:** Must use a 90-day pharmacy in the network, including Express Scripts Home Delivery Pharmacy
- **For 30-day fills:** Can use any pharmacy in the network

Did you know?

Those who fill a 90-day supply have **12% higher prescription adherence¹** than those who fill a 30-day supply.

1. Internal Cigna analysis performed Jan 2019, utilizing 2018 Cigna national book of business average medication adherence (customer adherent > 80% plan directed care), 90-day supply vs. those who received a 30-day supply taking antidiabetics, RAS antagonist and statins. Individual client results will vary and savings are not guaranteed.

Exclusive

Savings Opportunity \$10,132

Requires customers to fill maintenance medications in a 90-day supply at **retail or home delivery**.

- **For 90-day fills:** Must use a 90-day pharmacy in the network
- **For 30-day fills (of non-maintenance medications):**
Can use any pharmacy in the network

Client choice: 1, 2 or 3 fills allowed in a 30-day supply before the 90-day supply requirement applies

90-Day Maintenance Drug List – same as the one used for Exclusive Home Delivery





Maintenance Medication Program - Performance Analysis


WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

Performance summary


Cigna 90 Now: Voluntary

Maintenance Medications	<u>Base</u>	<u>Current</u>	<u>Opportunity</u>
30 Day Prescriptions			
Count	2,919	2,572	NA
Percentage	54.9%	55.2%	NA
90 Day Prescriptions			
Count	2,402	2,089	NA
Percentage	45.1%	44.8%	NA
Savings		\$9,175	\$10,132

Pharmacy utilization - maintenance prescriptions



Cigna 90 Now network access - 447 members



Comments

- Savings are driven both by lower network contracted rates and conversions to 90 Day maintenance prescriptions
- 30 Day RX's decreased 11.9% and 90 Day RX's decreased 13.0%
- The opportunity savings represents a 25% shift in utilization to 90 day. Adoption of Mandatory Cigna 90 Now estimated to yield additional PMPY savings
- Of the 131 customers filling 30 day prescriptions at Non-90 day retail pharmacies today, 90.8% are within 1.5 miles of a 90 day retail pharmacy
- Overall medication adherence for those customers using 90 day fills is 21.1% greater than those using 30 day fills

MEMBER ENGAGEMENT

Key Findings and Observations 2021

Top 5 Diagnosis



- Newborn
- Kidney/Urinary Tract
- Pregnancy
- Musculoskeletal
- Circulatory and Endocrine (tied for 5th)

Emergency Room & Urgent Care



- 170 ER visits by 108 unique members – 51 of those were steerable by 39 members; compared to 50 visits by 47 unique members during the same time period in 2020. Potential steerable savings was \$30,906.
- Urgent Care visits increased from 272 in 2020 to 296 during 2021.

Case Management



There were a total of 7 cases accepted of which 5 were managed, 2 were clinically non-appropriate for case management.

Health Information Line



There were 5 encounters total for the HIL, 4 for Network/Benefit/Other and 1 for Health Medical Information.

Emergency Room / Urgent Care

2020 & 2021



2020	
ER Summary	
Total ER Visits	156
Total Charge	\$184,803
Allowed Amounts	\$122,620
ER Cost per claim	\$786
UC Summary	
Total UC Visits	272
Total Charge	\$71,751
Allowed Amounts	\$43,961
UC Cost per Claim	\$162
Steerable ER Summary	
Steerable ER Visits	50
Unique Members	47
Potential Redirect Saving	\$31,200

2021	
ER Summary	
Total ER Visits	170
Total Charge	\$217,754
Allowed Amounts	\$143,606
ER Cost per claim	\$845
UC Summary	
Total UC Visits	296
Total Charge	\$99,412
Allowed Amounts	\$52,993
UC Cost per Claim	\$179
Steerable ER Summary	
Steerable ER Visits	51
Unique Members	39
Potential Redirect Saving	\$30,906

Lab Utilization

2020 & 2021



Savings using Quest or LabCorp

2020	Total Charges	Total Allowed	Total Savings	Claim Count	Cost per claim	% Savings
Quest & Labcorp	\$222,877	\$46,597	\$176,280	2,321	\$20	79%
All other In-net	\$250,067	\$135,964	\$114,104	1,907	\$71	46%
Total In-network	\$472,944	\$182,560	\$290,383	4,298	\$43	61%

2021	Total Charges	Total Allowed	Total Savings	Claim Count	Cost per claim	% Savings
Quest & Labcorp	\$262,946	\$54,772	\$208,173	2,772	\$20	79%
All other In-net	\$240,611	\$113,422	\$127,189	2,217	\$51	53%
Total In-network	\$503,557	\$168,195	\$335,362	4,989	\$34	67%

2022 Engagement Plan

	Action	Target	Communication
1	Continue to increase LabCorp & Quest utilization to increase savings for the fund	Increase INN National Lab utilization	Communication to members - via newsletter, website, or emails.
2	ER, UC and Convenience Care Center redirection; Promote MyCigna.com website and app use for quick reference	Reduce unnecessary & costly ER utilization. Encourage redirection of care.	Communication to members - via newsletter, website, or emails.

APPENDIX



RationalMed for Cigna

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND


RationalMed for Cigna is a gaps in care solution which sends alerts electronically and in real-time to providers to improve the health and safety of our customers while driving savings for our clients.



Gaps & Savings by Category

Alert Category	Examples	Gaps	Closures	Customers
Adverse Drug Risk	Drug/drug interaction, Drug/disease interaction	49	22	17
Coordination of Care	Multiple medications, Multiple prescribers	6	1	2
Omission of Care	Under dosing	0	0	0

Savings by Condition



Comments

- For the book of business, providers have also shared positive feedback on the usefulness & timeliness of the RationalMed alerts, and the organization & amount of information in the alerts.
- Under dosing gap closures may result in negative savings due to an increase in the dosage or strength of medication to support effective management of the condition the drug was prescribed to treat.



RationalMed for Cigna - Detail Summary

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

RationalMed for Cigna is a gaps in care solution which sends alerts electronically and in real-time to providers to improve the health and safety of our customers while driving savings for our clients.

Alert Category	Gaps	Closures	Closure Rate	Savings Total	Customers
Adverse Drug Disease Consideration	5	5	100%	\$0	2
Adverse Drug Interaction	20	5	25%	\$56	5
Dose Duration Consideration	8	3	38%	\$0	3
Drug Age Consideration	0	0	0%	\$0	0
Drug Pregnancy	0	0	0%	\$0	0
Drug Therapy Duplication	4	3	75%	-\$8	2
Duration Consideration	5	1	20%	\$0	3
Excessive Dosing	1	1	100%	\$0	1
High Risk Medications	5	4	80%	\$34	4
Quantity Considerations	1	0	0%	\$0	1
Pharmacogenomics	0	0	0%	\$0	0
Subtotal: Adverse Drug Risk	49	22	45%	\$121	17
Misuse/Abuse	0	0	0%	\$0	0
Polypharmacy	6	1	17%	\$7	2
Subtotal: Coordination of Care Opportunity	6	1	17%	\$479	2
Under Dosing	0	0	0%	\$0	0
Subtotal: Omission of Essential Care	0	0	0%	\$0	0
Total	55	23	42%	\$600	17



High Cost Claimants - Pharmacy Benefit Drug Spend

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

High cost claimants

<u>Rank</u>								
Base	Current	Gender	Age	Relationship	Condition	Pharmacy	Drug	
2	1	M	50-59	Employee	RA/Psoriasis/Crohn's	\$76,033	Humira (SRx)	
3	2	M	50-59	Employee	RA/Psoriasis/Crohn's	\$64,829	Humira (Cf) (SRx)	
6	3	M	50-59	Employee	Antivirals, HIV Specific	\$43,733	Biktarvy (SRx)	
7	4	M	60-64	Employee	Antivirals, HIV Specific	\$33,746	Odefsey (SRx)	
358	5	M	30-39	Employee	Hepatitis A/B/C	\$33,661	Harvoni (SRx)	
4	6	F	60-64	Spouse	RA/Psoriasis/Crohn's	\$30,439	Actemra (SRx) ,Xeljanz (SRx)	
-	7	F	18-29	Dependent	Asthma Related	\$29,755	Dupixent (SRx)	
12	8	M	65+	Employee	Insulins	\$24,772	Humalog,Tresiba	
11	9	F	65+	Spouse	Cardiovascular Related	\$24,038	Entresto	
1	10	F	50-59	Spouse	Multiple Sclerosis	\$19,702	Gilenya (SRx)	
5	11	M	50-59	Employee	Antivirals, HIV Specific	\$19,038	Atripla (SRx),Efavirenz-Emtric	
16	12	M	40-49	Spouse	Hypoglycemics	\$18,407	Trulicity,Synjardy	
10	13	M	50-59	Employee	Multiple Sclerosis	\$17,249	Dalfampridine	
13	14	F	50-59	Employee	Hypoglycemics	\$15,303	Trulicity	
8	15	M	60-64	Employee	Hypoglycemics	\$12,555	Farxiga,Trulicity	
19	16	M	60-64	Employee	Hypoglycemics	\$11,930	Jardiance,Janumet	
20	17	M	50-59	Employee	Hypoglycemics	\$11,651	Ozempic	
31	18	F	40-49	Spouse	Antivirals, HIV Specific	\$11,006	Biktarvy (SRx)	
14	19	F	40-49	Spouse	Antivirals, HIV Specific	\$10,985	Biktarvy (SRx)	
24	20	M	40-49	Employee	Hypoglycemics	\$10,713	Trulicity	
9	21	M	40-49	Employee	Insulins	\$9,453	Humalog,Levemir	
22	22	F	50-59	Spouse	Asthma Related	\$7,501	Atrovent,Breo	
41	23	M	65+	Employee	Asthma Related	\$7,385	Atrovent	
25	24	M	60-64	Employee	Hypoglycemics	\$6,277	Glyxambi	
32	25	M	65+	Employee	Asthma Related	\$6,260	Trelegy,Breo	

* Pharmacy dollars represent pharmacy benefit drug costs

* SRx - Specialty Pharmacy



Specialty Pharmacy - Top Drug Spend

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

Top drugs by spend

Rank		Drug Name	Condition	Plan Spend	Members		Claims	
Base	Current				Base	Current	Base	Current
2	1	Biktarvy(SRx)	Antivirals, HIV Specific	\$68,987	3	4	21	19
4	2	Humira Pen(SRx)	RA/Psoriasis/Crohn's	\$64,072	1	1	8	10
3	3	Humira(Cf) Pen(SRx)	RA/Psoriasis/Crohn's	\$63,965	2	1	11	10
-	4	Harvoni(SRx)	Hepatitis A/B/C	\$33,643	-	1	-	1
6	5	Odefsey(SRx)	Antivirals, HIV Specific	\$32,959	1	1	12	10
-	6	Dupixent Syringe(SRx)	Asthma Related	\$27,918	-	1	-	9
-	7	Actemra(SRx)	RA/Psoriasis/Crohn's	\$24,146	-	1	-	11
1	8	Gilenya(SRx)	Multiple Sclerosis	\$19,211	1	1	12	2
5	9	Atripla(SRx)	Antivirals, HIV Specific	\$16,621	1	1	14	8
9	10	dalfampridine er	Multiple Sclerosis	\$14,187	1	1	11	10
7	11	Humira(SRx)	RA/Psoriasis/Crohn's	\$6,303	1	1	4	1
16	12	emtricitabine- tenofovir disop	Antivirals, HIV Specific	\$5,642	1	1	1	5
8	13	Xeljanz(SRx)	RA/Psoriasis/Crohn's	\$5,208	1	1	3	1
-	14	efavirenz-emtric- tenofov disop	Antivirals, HIV Specific	\$2,050	-	1	-	1
15	15	gengraf	IVIG/Immune-related	\$863	1	1	20	12
		All Other Specialty		\$706	11	4	35	6
Total				\$386,483	21	19	152	116

Comments

- The top fifteen Specialty Pharmacy and Medical drugs accounted for 99.8% (\$385,777) of the total Specialty plan spend (\$386,483) in the current period.
- The Specialty Top Drugs are: Biktarvy, Humira Pen, and Humira (Cf) Pen.



Top Therapeutic Class Trend

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

Therapeutic class trend driver analysis by plan spend

Base Rank	Current Rank	Therapeutic Class	Condition	Unique Members
				Current
2	1	Anti-Inflam Disease Modifiers	Arthritis	3
1	2	Antivirals, HIV Specific	HIV	7
4	3	Hypoglycemics	Diabetes	43
6	4	Asthma Related	Asthma	61
5	5	Insulins	Diabetes	11
-	6	Hepatitis A/B/C	Hepatitis	1
3	7	Multiple/Lateral Sclerosis	Multiple Sclerosis	2
-	8	Vaccines	Vaccine	278
7	9	ACE/ARB	Hypertension	97
10	10	Lipid Lowering	Cholesterol	83
8	11	Antiulcer	Ulcer / Heartburn	48
11	12	Beta Blockers	Heart/Hypertension	45
14	13	Eye	Glaucoma	25
15	14	Diabetic Supplies	Diabetes	11
13	15	Nepriylsin Inhibitors	Heart	2
		All Other		358
Total				466

Comments

- The top 15 therapy classes accounted for 88.4% (\$3,751.76) of total plan spend



Top Drugs by Spend

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

Top drugs by spend

Rank		Drug Name	Condition	Plan Spend Current	Unique Members		Scripts	
Base	Current				Base	Current	Base	Current
2	1	Biktarvy (SRx)	HIV	\$68,987	3	4	21	19
4	2	Humira Pen (SRx)	Arthritis	\$64,072	1	1	8	10
3	3	Humira(Cf) Pen (SRx)	Arthritis	\$63,965	2	1	11	10
6	4	Trulicity	Diabetes	\$35,947	5	5	50	45
-	5	Harvoni (SRx)	Hepatitis	\$33,643	0	1	0	1
7	6	Odefsey (SRx)	HIV	\$32,959	1	1	12	10
-	7	Dupixent Syringe (SRx)	Asthma	\$27,918	0	1	0	9
-	8	Actemra (SRx)	Arthritis	\$24,146	0	1	0	11
1	9	Gilenya (SRx)	Multiple Sclerosis	\$19,211	1	1	12	2
5	10	Atripla (SRx)	HIV	\$16,621	1	1	14	8
15	11	Farxiga	Diabetes	\$15,098	4	4	26	30
12	12	dalfampridine er (SRx)	Multiple Sclerosis	\$14,187	1	1	11	10
9	13	Ozempic	Diabetes	\$13,762	3	4	28	18
10	14	Tresiba Flextouch U-200	Diabetes	\$11,739	3	2	30	18
13	15	Januvia	Diabetes	\$11,650	4	4	32	24
19	16	Humalog Kwikpen U-100	Diabetes	\$11,466	2	3	17	14
14	17	Breo Ellipta	Asthma	\$11,384	6	6	40	31
29	18	Jardiance	Diabetes	\$10,819	2	4	13	20
25	19	Atrovent Hfa	COPD	\$9,712	3	2	17	23
-	20	Advair Diskus	Asthma	\$9,482	0	5	0	24



High Cost Prescriptions

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

High cost prescriptions ranking

Rank		Drug Name	Condition	Cost per Script Current	Unique Members		Scripts	
Base	Current				Base	Current	Base	Current
-	1	Harvoni (SRx)	Hepatitis	\$33,643	0	1	0	1
1	2	Gilenya (SRx)	Multiple Sclerosis	\$9,606	1	1	12	2
3	3	Humira Pen (SRx)	Arthritis	\$6,407	1	1	8	10
4	4	Humira(Cf) Pen (SRx)	Arthritis	\$6,397	2	1	11	10
2	5	Humira (SRx)	Arthritis	\$6,303	1	1	4	1
5	6	Xeljanz (SRx)	Arthritis	\$5,208	1	1	3	1
6	7	Biktarvy (SRx)	HIV	\$3,631	3	4	21	19
8	8	Odefsey (SRx)	HIV	\$3,296	1	1	12	10
-	9	Dupixent Syringe (SRx)	Asthma	\$3,102	0	1	0	9
-	10	Actemra (SRx)	Arthritis	\$2,195	0	1	0	11
10	11	Atripla (SRx)	HIV	\$2,078	1	1	14	8
-	12	efavirenz-emtricitenofovir disop (SRx)	HIV	\$2,050	0	1	0	1
14	13	dalfampridine er (SRx)	Multiple Sclerosis	\$1,419	1	1	11	10
-	14	Latuda	Psychosis	\$1,326	0	1	0	2
12	15	emtricitabine-tenofovir disop (SRx)	HIV	\$1,128	1	1	1	5
17	16	Humalog Mix 75-25 Kwikpen	Diabetes	\$1,045	1	1	12	5
21	17	Ubrelyv	Migraine	\$880	1	1	1	1
28	18	Humalog Kwikpen U-100	Diabetes	\$819	2	3	17	14
23	19	Trulicity	Diabetes	\$799	5	5	50	45
-	20	Rybelsus	Diabetes	\$773	0	1	0	6

Comments

- The top 20 high cost drugs accounted for 2.4% (171 scripts) of the overall prescription volume



Pharmacy Drug Utilization Management Performance

WAREHOUSE EMPLOYEES LOCAL 730 H&W FUND

Savings summary


Edit Type	Impacted Members	Savings
Baseline*	93	\$16,054
Specialty Utilization Management	1	\$8,780
Quantity Limits	17	\$2,329
Step Therapy	2	\$1,885
Prior Authorization	1	\$353
Total	105	\$29,400

* Programs within this group are Refill Too Soon, Dose Optimization (DACON), Quantity over time, certain age limits, maximum dose, cost, and quantity per script

Savings by therapeutic class

Therapeutic Class	Impacted Members	Savings
Hypoglycemics	17	\$10,588
Anti-Inflam Disease Modifiers	1	\$8,780
ACE/ARB	27	\$3,047
Beta Blockers	10	\$3,027
Insulins	2	\$2,337
Asthma Related	10	\$1,910
Impotency Related	10	\$1,184
Antiulcer	12	\$1,053
Antivirals, HIV Specific	1	\$652
All Other	70	\$5,097

Specialty UM: Members impacted by therapeutic class



Specialty UM savings : \$8,780

Comments

- A total of 105 members were impacted through various utilization management programs that resulted in savings of \$29,400
- The greatest savings were driven by the Baseline edits
- Specialty UM savings - top therapeutic classes : Anti-Inflam Disease Modifiers, Antivirals, HIV Specific
- The pharmacy utilization management package helps protect against potentially harmful, ineffective or unnecessary drug treatments and rising drug costs by checking for:
 - Customer diagnosis matches clinical guidelines for use
 - Clinically appropriate quantity, dose, and duration of use
 - Error, inappropriate drug use and opportunity to reduce waste
 - Promotion of safe and effective drugs that deliver better value
 - Specialty medication coaching, specialty condition support and holistic health coaching opportunities

Offered by: Connecticut General Life Insurance Company or Cigna Health and Life Insurance Company.

“Cigna” and the “Tree of Life” logo are registered service marks, and “Together, all the way.” is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries, including Connecticut General Life Insurance Company and Cigna Health and Life Insurance Company, and not by Cigna Corporation. All models are used for illustrative purposes only.

000000 00/16 © 2022 Cigna. Some content provided under license.